



April 10, 2026

"AMGA Immunizations Brief"—brought to you by the Rise to Immunize® (RIZE) campaign—delivers vaccine news and updates relevant to healthcare leaders. This brief provides concise, actionable information to help you stay informed and guide patient care in an evolving immunization landscape.

Check out our newly launched [AMGA Immunizations Hub](#) for critical immunization resources.

For a more in-depth weekly report, sign up for the [Vaccine Intelligence Report](#) from RIZE campaign partner [Vaccinate Your Family](#).

At a Glance

- HHS has moved to renew ACIP's charter, paving the way for reconstitution.
- Pfizer and BioNTech have paused a post-marketing COVID-19 vaccine trial due to low enrollment.
- The CDC has temporarily paused testing for more than two dozen infectious diseases.
- New research highlights vaccine benefits, uptake challenges, and the role of communication.

Detailed Brief

HHS has moved to renew ACIP's charter, paving the way for reconstitution.

- The Department of Health and Human Services (HHS), under Secretary Robert F. Kennedy Jr., is moving to [renew the charter](#) of the Advisory Committee on Immunization Practices (ACIP).
- The charter renewal notice [removes earlier language](#) requiring committee members to have specific expertise in vaccines and immunization, replacing it with broader and less defined qualification criteria for members.
- While charter renewals are a [routine administrative step](#) for federal advisory committees, these changes to membership criteria could influence how the panel is reconstituted and give Kennedy greater flexibility in selecting members.
- If ACIP is reconstituted under these new criteria, the committee could revisit or reintroduce vaccine guidance changes made over the past year—including [revisions to the childhood immunization schedule](#) that were [blocked by the court](#).

Pfizer and BioNTech have paused a post-marketing COVID-19 vaccine trial due to low enrollment.

- Pfizer and BioNTech have [halted](#) a U.S. study of their updated COVID-19 vaccine after struggling to enroll enough participants, in turn limiting the ability to generate meaningful data.

- The [placebo-controlled trial](#) was part of a post-marketing study tied to [Food and Drug Administration requirements](#) introduced last year. The trial was halted solely due to recruitment challenges, not because of any safety or efficacy concerns.
 - Post-marketing studies allow for the collection of additional data to address targeted or long-term questions once safety and efficacy have been established.

The CDC has temporarily paused testing for more than two dozen infectious diseases.

- The Centers for Disease Control and Prevention (CDC) has [paused tests](#), including those for common infections such as the Epstein-Barr virus; the varicella zoster virus, which causes chickenpox and shingles; and respiratory panel tests that detect the viruses that cause COVID-19, influenza A and B, rabies, and other less common infectious diseases.
- While the reason for the pause is unclear, the CDC [said](#) it will still support state and local public health agencies in accessing testing and that some tests are available commercially.

New research highlights vaccine benefits, uptake challenges, and the role of communication.

- A [large study](#) of older adults found that high-dose influenza vaccination was associated with a nearly 55% lower risk of Alzheimer's disease compared to standard-dose vaccines, which are associated with a 40% reduction in risk.
- A recent [retrospective cohort study](#) of more than 76,000 immunocompromised cancer patients showed that receiving updated COVID-19 vaccines was linked to lower risk of long COVID-19 during the Omicron wave.
- A [study](#) of healthcare professionals found that 76% of those surveyed received flu vaccines, compared to just 40% for COVID-19 vaccines. Workplace access, such as offering vaccines on site, was strongly associated with higher uptake.
- A [recent study](#) found that older adults who were hesitant about COVID-19 vaccines were more likely to express willingness to vaccinate when framed to preserve freedom and autonomy, as opposed to a way to comply with government recommendations.

If you no longer wish to receive the "AMGA Immunizations Brief," please [unsubscribe here](#).